Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Second Quarter 2024
- Total revenue increased 12 per cent, 11 per cent at constant exchange rates, (CER), to
SEK 5,442 M (4,872) - Haematology revenue increased 13 per cent at CER to
SEK 3,866 M (3,430), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® excluding sales toChina ofSEK 928 M (567), sales of Vonjo® ofSEK 347 M (36) and sales of Aspaveli®/Empaveli® ofSEK 251 M (144) - Immunology revenue increased 7 per cent at CER to
SEK 1,277 M (1,179), driven by strong sales of Kineret® ofSEK 745 M (661) and Gamifant® ofSEK 522 M (491) - Revenue from medicines in the strategic portfolio grew by 74 per cent at CER to
SEK 2,219 M (1,258) - The adjusted EBITA margin was 28 per
cent (26) , excluding items affecting comparability (IAC). EBITA wasSEK 1,486 M (1,009), corresponding to a margin of 27 percent (21) . EBIT wasSEK 612 M (413) - Earnings per share (EPS) before dilution was
SEK 0.66 (0.71). Adjusted EPS before dilution wasSEK 0.72 (1.41). Cash flow from operating activities wasSEK 2,329 M (357) - Altuvoct® (efanesoctocog alfa) was EU approved for once-weekly treatment of haemophilia A
- Aspaveli was EU approved for use among treatment naïve adult patients with PNH
- Biologics license application to FDA initiated for SEL-212 for the potential treatment of chronic refractory gout
Outlook 2024 - updated
- Revenue is anticipated to grow by low double-digit percentage at CER (previously high single-digit)
- The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue (unchanged)
The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding
Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
For other countries, please find the details here.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Strong delivery driven by robust portfolio performance |
View original content:https://www.prnewswire.co.uk/news-releases/sobi-q2-2024-report-strong-delivery-driven-by-robust-portfolio-performance-302197918.html